BCM
CTMX icon

Burrage Capital Management’s CytomX Therapeutics CTMX Stock Holding History

Burrage Capital Management’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-482,982
Closed -$3.46M – 27
2020
Q1 		$3.46M Buy
482,982
+6,872
+1% +$47.9K 3.41% 13
2019
Q4 		$3.96M Buy
+476,110
New +$3.21M 2.65% 15

Other funds holding CTMX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Burrage Capital Management's CTMX Position: Q2 2020 in Review

Burrage Capital Management sold out of CytomX Therapeutics (CTMX) in Q2 2020, closing a stake of 482,982 shares — an estimated $3.46M sold.

Burrage Capital Management first reported a position in CTMX in Q4 2019 and held it in 2 quarters. The position peaked at $3.96M in Q4 2019. 134 funds tracked by Wall St. Rank hold CTMX as of Q2 2020.

  • Burrage Capital Management reported no remaining CytomX Therapeutics position as of Q2 2020 after selling out during the quarter.
  • Burrage Capital Management sold 482,982 CytomX Therapeutics shares in Q2 2020, an estimated $3.46M.
  • Burrage Capital Management first reported a position in CytomX Therapeutics in Q4 2019 and held it in 2 quarters.
  • Burrage Capital Management's CytomX Therapeutics position peaked at $3.96M in Q4 2019.
  • 134 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2020.

Based on Burrage Capital Management's 13F filing for Q2 2020, filed 14 Aug 2020.